Table 1.
In glioma: clinical trials of IDH1/2 inhibitors, vaccines and new uses for old drugs.
| ClinicalTrials.gov | Drug | Phase | Study title | References |
|---|---|---|---|---|
| NCT02073994 | AG-120 | II | Study of AG-120 in subjects with advanced solid tumors, including glioma with an IDH1 mutation | (33) |
| NCT03343197 | AG-120+AG-881 | II | Study of AG-120 and AG-881 in subjects with low grade glioma | (34) |
| NCT02273739 | AG-221 | I II | Study of orally administered AG-221 in subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell lymphoma, with an IDH2 mutation subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell | (35) |
| NCT02454634 | IDH1 peptide vaccine | I | Phase I trial of IDH1 peptide vaccine in IDH1R132H-mutated grade III-IV gliomas IDH1 | (36) |
| NCT02193347 | IDH1peptide vaccine | I | IDH1 peptide vaccine for recurrent grade II glioma (RESIST) | (37) |
| NCT02771301 | IDH1R132H-DC vaccine | I | Safety and efficacy of IDH1R132H-DC vaccine in gliomas | (38) |
| NCT03666559 | Azacitidine | II | Treatment with azacitidine of recurrent gliomas with IDH1/2 mutation | (39) |
| NCT03557359 | Nivolumab | II | Nivolumab for recurrent or progressive IDH mutant gliomas | (40) |
| NCT02766270 | Temozolomide | Early phase I | CCRT with temozolomide vs. RT alone in patients with IDH wild-type/TERT promoter mutation grade II/III gliomas | (41) |
| NCT02209428 | Temozolomide | II | Prospective cohort to study the effect of temozolomide on IDH mutational low-grade gliomas | (42) |
| NCT03684811 | FT-2102+azacitidine | I and II | Study of FT 2102 in participants with advanced solid tumors and gliomas with an IDH1 mutation | (43) |